Getting advice on IPOs from a broker or analyst is like asking the owner of a restaurant whether the entrées on the menu are any good.

Why make investment decisions based on the recommendations of brokers and analysts who may not have your best interests at heart?

Our seasoned chefs provide:

Candid, unbiased analysis

Detailed information on recent IPOs and SPACs

The recipe to make your own informed investment decisions

 
 

×

 
 
×

Cart

 

No products in the cart.

 

 

Alumis – Could This Broken Immunology IPO Become the Next Amgen?

With a drug in advanced testing for two different indications that have spawned blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? We kick the tires on this broken IPO, examine the trial results of their lead psoriasis drug, and give you our prescription.

Blaize Inc. SPAC Merger – Video Commentary

We slice and dice the upcoming Blaize Inc. SPAC merger and dish out our candid opinion on the offering. Is this hot AI play ready to set the market on fire?

Webtoon Entertainment IPO – Video Commentary

We slice and dice the upcoming Webtoon Entertainment IPO and dish out our candid opinion on the offering. Is the company ready to write the next chapter of its story or is it better to remain on the sidelines and see how the plot develops?

Webtoon Entertainment – Writing the Next Chapter

The popular online storytelling platform, Webtoon Entertainment, is set to debut on the NASDAQ next week, but after nearly a decade of high-flying growth in East Asian markets, the company’s sales engine is sputtering. Can they recapture their magic and make an animated foray into international markets or will this be just another tale with a tragicomic ending?

Are Webullish on Webull?

The excitement was palpable when SK Growth Opportunities (SKGR) announced a business combination with Webull in February. The digital brokerage has been expanding into new markets at a frenetic pace, capturing market share from more established brokers. But with growing concerns about Chinese owned-companies, will the merger go through or will it languish under the watchful eye of the CFIUS?

Blaize Saddling Up for a Blistering NASDAQ Debut

Investors have been eagerly awaiting Blaize's business combination with the SPAC BurTech Acquisition Corp. (BRKH). But can the company compete with Nvidia, AMD, Intel, and the rest of the big boys on the block to lasso a piece of the rapidly expanding AI market?

confused man

Public domain

Did retail investors misinterpret CG Oncology's Phase-3 readout?

Investors were apparently unimpressed with the complete response rate CG Oncology (CGON) reported in non-muscular invasive bladder cancer on May 3rd, with the shares plunging up to 23% at one point. But in looking at the Anktiva data, were they comparing apples to oranges?

CG Oncology IPO Likely to Receive a Warm Reception

With a lead bladder cancer drug in advanced Phase-3 testing and a severe shortage of the standard-of-care treatment, could this immunotherapy company relieve the IPO market from its doldrums?

Srivaru CEO Mohan Ramasamy with Prana bike

Image courtesy of Srivaru Holding Limited

Srivaru Motors: An Exclusive Interview with CEOs Mohan Ramaswamy and Peter Bilitsch After the Company's Debut on the Nasdaq

With ample funding and a former Tesla engineering executive at the helm, Srivaru has the hole shot in the race to capture the fast-growing Indian electric motorbike market. We were privileged enough to get a first-hand look into the company's strategy, product positioning, and marketing initiatives.

Ryde Group: Brace Yourself for a Bumpy Ride!

Ryde is about to launch a micro-IPO on the NYSE at a premium valuation, but can we really assume they'll be able to steer clear of all the hazards without blowing a tire?

social influencer in the kitchen
Image by rawpixel.com

WeBuy - Fresh fruit or rotting vegetables?

After doubling its sales last year, Southeast Asian social commerce upstart WeBuy is cashing in and going public. But is their revenue growth sustainable in light of mounting competition and frequent delivery snafus?

illustration of a vaccine molecule
Illustration by Ri Ya

RayzeBio - Raising the bar in solid tumor radiotherapy

Thanks to recent market turbulence, RayzeBio has now fallen near the IPO offer price. With a lead radiotherapy drug in advanced Phase 3 testing, upcoming catalysts, and multiple shots on goal, is it a good time to pick up some shares?

Instacart: Losing Momentum As It Approaches the Checkout Aisle?

Instacart, the popular online grocery website, is going public on Tuesday but with GTV and order growth slowing will the company be able to fend off the competition and make it to the finish line?

ARM Holdings: Plenty of Smoke But No Fire

The upcoming ARM Holdings Initial Public Offering is almost certain to be wolfed down by eager retail investors who've endured slim pickings since the pandemic, but is this hot item truly worth the extra calories?